FDA shuts down firm's supplement sales over presence of APIs

By Hank Schultz contact

- Last updated on GMT

FDA shuts down firm's supplement sales over presence of APIs
Another dietary supplement manufacturer has been shut down by FDA, in this case for including illicit active pharmaceutical ingredients in its products.

Last week a federal court in Florida entered a consent decree of permanent injunction between the United States and a company called MyNicNaxs, LCC and two principals, owner Chevonne Torres and Michael Brenner, a company officer.

MyNicNaxs distributed weight loss and sexual enhancement products to consumers through two websites. The company also sells a variety of body slimming devices such as corsets and sexual paraphernalia, which are still for sale on the company’s website.

Undeclared APIs not only illegal, but risky

According to FDA, some of the company’s products, which were sold as dietary supplements, tested positive for APIs commonly found in weight loss and sexual enhancement products.

"Marketing products with undeclared active pharmaceutical ingredients poses serious safety risks to consumers. These types of products are particularly concerning because consumers do not know what the products actually contain, and the undeclared ingredients may cause serious, even life threatening, adverse reactions,"​ said Donald D. Ashley, director of the Office of Compliance in the FDA's Center for Drug Evaluation and Research. "Despite previous warnings, MyNicNaxs continued violating the law. The FDA will continue to take action to protect the American public when companies knowingly violate the law and put consumers at risk.”

Rouges gallery of APIs

According to the complaint filed with the consent decree, FDA tests showed some of the MyNicNaxs products contained undisclosed pharmaceutical ingredients such as:

  • Sildenafil​, the active pharmaceutical ingredient in Viagra.  This ingredient, and the many analogues thereof, have been found in many products aimed at erectile dysfunction. As vasodilators, the undeclared presence of these drugs could harm the health of consumers who are already on blood pressure medications.
  • Sibutramine​.  This weight loss drug was marketed under the brand name Merida before it was withdrawn from the market after clinical data indicated that it poses an unacceptable increased risk of heart attack and stroke.
  • Phenolphthalein​ is a laxative ingredient that the FDA deemed "not generally recognized as safe and effective"​ after studies indicated that it was a potential carcinogen.

The presence of this ingredient (and that of sibutramine) in tainted products is nothing new; as far back as 2009 FDA identified almost 70 products on the market containing these and other illicit APIs​. Sildenafil and its analogues as potential adulterants appears to have come on the agency’s radar somewhat later.

The permanent injunction requires the defendants to cease directly or indirectly distributing any unapproved new drugs or misbranded drugs. MyNicNaxs is prohibited from receiving, manufacturing, holding and distributing any drugs or dietary supplements until they receive a written notification from the FDA stating that they appear to be in compliance with the decree, the FD&C Act, and its regulations, and that they may resume operations.

Long road to injunction

The road that led to the injunction filed against MyNicNaxs had its start more than five years ago, as detailed in a warning letter FDA sent to the company in 2015​.  The company first came into FDA’s crosshairs when a package meant for the company was intercepted in 2013 and found to contain sibutramine and phenolphthalein. In 2014 the company agreed to recall the offending products, but received additional shipments of tainted product later in 2014 and continued to distribute products containing illicit ingredients up to the receipt of the warning letter in February, 2015.  That warning letter did not mention the presence of sildenafil in any of the company’s products.

 

 

 

 

Related news

Show more

Related products

show more

Gemini Pharmaceuticals and Transparency

Gemini Pharmaceuticals and Transparency

Gemini Pharmaceuticals | 01-Sep-2019 | Application Note

The industry has shown improvement in its transparency in the past 5 years. Per the regulations, a Brand Owner is 100% responsible for the quality of...

Clinically Proven Omega-3 formula for Joint Health

Clinically Proven Omega-3 formula for Joint Health

KD Pharma Group | 01-Sep-2019 | Data Sheet

KD Nutra is pleased to announce the completion of a clinical trial for its Move3™ omega-3 joint formulation. The trial has shown that Move3™ has a significant...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars